FEM1B and cholangiocarcinoma: Therefore, we hypothesize that agonistic compounds of the FEM1B-CUL2 E3 ubiquitin ligase complex could be suitable therapeutic tools that degrade BEX2 proteins in cholangiocarcinoma stem cells.